focus -WSS

focus

author：explore 2025-10-01 21:48:10 - browse：1

A view of different flags of the European Union Members. -- first opinion coverage from STAT — Ronald Wittek, Pool Photo via AP

Today, the criteria used to assess the clinical value of new pharmaceuticals and medical devices varies widely across Europe, making it more challenging for biopharma companies to efficiently launch products in multiple countries and contributing to the disparities in access across the continent.

But change is on the horizon: In less than 15 months, the European Union will establish and begin to implement a standardized, pan-EU framework, which all 27 of member states will be required to use to assess the clinical evidence of newly submitted products or devices. A key pillar of the EU’s Regulation on Health Technology Assessment (HTA), the Joint Clinical Assessment (JCA) aims to establish a single, transparent process to reduce redundant practices and bring life science innovation faster to patients in Europe — no matter where they live.

In a longstanding problem in Europe, access to — and the availability of — medication varies across the member states. For example, in Germany, 87% of products approved by the European Medicines Agency (EMA) have full availability (the product gained access on the public reimbursement list without any restrictions to the patient population). In Poland, that figure drops to 8%, according to a report published by the European Federation of Pharmaceutical Industries. Meanwhile, there is a tremendous difference in the gap between an oncology therapy receiving marketing authorization and a formal positive reimbursement decision, ranging from an average of 86 days in Denmark to 981 days in Latvia.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Apple is now the first public company to be valued at $3 trillion
Next article： Biotech stock slump in 2023: awaiting the turnaround

WSS

Physician groups backed by private equity giant lobby on mergers

Readout LOUD podcast: possible new ALS drug, artificial wombs

Microbiome research is starting to find links to chronic diseases

Pence says 'crackpot lawyers' told Trump what he wanted to hear

Breakthrough Alzheimer’s drugs are inaccessible in rural states

Ukraine and a new approach to mental health in war

focus

focus

hotspot

Duchenne breakthrough therapy leaves behind pioneering families

Canadian Prime Minister Justin Trudeau separating from wife, Sophie

Medical leaders decry Supreme Court decision on affirmative action

Second xenotransplant done with gene

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Micronoma's microbiome cancer diagnostic approach under fire

Trump demands the U.S. pay no more for drugs than other countries … again

Infectious disease expert Jeanne Marrazzo assumes Fauci role

Tori Bowie and the unacceptable rates of Black maternal death

Breakthrough Alzheimer’s drugs are inaccessible in rural states

leisure time

EQRx, failed developer of low

How AI helped researchers track recovery from depression

FDA panel to weigh approval of NurOwn, controversial ALS drug

CDC advisers recommend seasonal use of Pfizer RSV shot

Second xenotransplant done with gene

Sage hopes for a blockbuster in antidepressant now before FDA

Wikipedia

Wikipedia

knowledge

hotspot